About Dermiria
Dermiria is a publicly listed company based in Redwood City (United States) founded in 2011, and was acquired by Lilly in January 2020. Dermatology therapies for psoriasis, hyperhidrosis, and acne are developed. Dermiria has raised $162.01 million across 9 funding rounds from investors including Lilly, UCB and Canaan. The company has 4 employees. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include Revance Therapeutics, MacroGenics and Kodiak Sciences; 3 of its 3 listed competitors have raised funding.
Company details
Dermira was founded in 2011 in Redwood City, United States, as a late-stage biotechnology firm. Operations center on the development and commercialization of dermatological treatments. The portfolio features three candidates: certolizumab pegol in phase 3 for moderate to severe plaque psoriasis, a topical agent in phase 3 for hyperhidrosis, and a sebum inhibitor in phase 2b for acne. Focus remains on innovative topical solutions within the sector.
- Headquarters Redwood City, United States
- Employees 4
- Stage Acquired
- SectorsHealthcare
- Website dermira.com
- Social LinkedIn
- Acquired by Lilly (Jan 2020)
Funding Insights of Dermiria
Dermiria has successfully raised a total of $162.01M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $162.01M
- Total Rounds 9
- Last Round Post-IPO — $1M
- First Round $42M
(Oct 2011)
- Investors Count 9
All 9 funding rounds of Dermiria with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $1M | Post-IPO | – | – | – |
| Dec 2018 | $125M | Debt – Conventional | – | – | |
| Dec 2017 | $500,000 | Post-IPO | – | – | – |
| May 2017 | $287.5M | Post-IPO | – | – | – |
| Sep 2016 | $1.5M | Post-IPO | – | – | – |
| Sep 2014 | $51M | Series C | – | Aisling Capital, Apple Tree Partners | |
| Jun 2013 | $35M | Series B | – | – | |
| Aug 2012 | $34.01M | Series B | – | – | – |
| Oct 2011 | $42M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in Dermiria
Dermiria has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, UCB and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Apple Tree Partners is engaged in life sciences venture capital. | appletreepartners.com | |||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Therapies for immunological and neurological disorders are developed. | 1928 | ucb.com | Brussels, Belgium | |
Conducts R&D and manufactures ethical drugs for healthcare applications. | 1915 | maruho.co.jp | Osaka, Japan | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States |
Investor details for Dermiria
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dermiria
166 people are tracked at Dermiria (123 in leadership, 11 in board & advisors, 32 in team); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Anna M Szpurka | Executive Director | Leadership |
Jessica Roberts | Sr. Director - Patent Counsel | Leadership |
Jamie Preston | Vice President HR Global Compensation | Leadership |
Ann Chen | VP - Global Brand Attorney | Leadership |
Thomas Lee | Senior Director | Leadership |
Anne White | President - Lilly Neuroscience | Leadership |
Kristen Dean | Executive Director Immunology Customer Strategy | Leadership |
Anne E. White | SVP & President, Lilly Oncology | Leadership |
Patrik Jonsson | SVP & President, Lilly Bio-Medicines | Leadership |
André Schönichen | Director, Diagnostics Development | Leadership |
Kapil Kamat | Sr. Director, Technology | Leadership |
Malika Mahoui | Associate Director- IT | Leadership |
Edgardo Hernandez | SVP & President, Manufacturing Operations | Leadership |
Sharanya Murty | Senior Director, Health Outcomes And Real World Evidence | Leadership |
Chris Anderson | Vice President, Leader Of Corporate Securities & Assistant Corp. Secretary | Leadership |
Nicholas Kunz | Senior Director - Patent Counsel, Neuroscience | Leadership |
Ben Thompson | Senior Director | Leadership |
Andrea Abell | Chief Information Security Officer | Leadership |
Jason Yazell | Sr. Director - Explor&d - AI & Automation Transformation | Leadership |
Valorie Wanner | Associate Vp-assistant General Counsel-corporate Securities And Assistant Secretary | Leadership |
146 more people are available in the full profile.
Complete people profiles for Dermiria
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dermiria
Dermiria is a publicly listed company on the NASDAQ with ticker symbol DERM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Oct 2014
- Listed onNASDAQ: DERM
- Listed entityJourney Medical Corporation
- Exchange sectorHealth technology
Timeline of Dermiria
5 dated milestones of Dermiria across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Dermiria is founded.
- Funding First funding round of $42.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $1.0M.
- Exit Acquired by Lilly.
Competitors of Dermiria
Dermiria has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, MacroGenics and Kodiak Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. | |
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. |
Detailed competitors of Dermiria
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dermiria
Websites that share an audience with Dermiria (dermira.com).
Websites whose visitors overlap most with Dermiria. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ardelyx.com | 100% | 17.8K | #2,305,983 | View details | |
| halozyme.com | 99% | 11.6K | #1,481,510 | View details | |
| dermtech.com | 97% | 2.8K | #8,199,657 | View details |
Top companies in Dermatology
3 companies that operate in the same segment as Dermiria (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dermiria
Complete news archive for Dermiria
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dermiria
Dermiria was founded in 2011.
Dermiria is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Dermiria is a funded company, having raised a total of $162.01M across 9 funding rounds to date. The company's 1st funding round was a Series A of $42M, raised on Oct 2011.
Dermiria has 4 employees.
Dermira was founded in 2011 in Redwood City, United States, as a late-stage biotechnology firm. Operations center on the development and commercialization of dermatological treatments. The portfolio features three candidates: certolizumab pegol in phase 3 for moderate to severe plaque psoriasis, a topical agent in phase 3 for hyperhidrosis, and a sebum inhibitor in phase 2b for acne. Focus remains on innovative topical solutions within the sector.
Dermiria's top competitors include Revance Therapeutics, Kodiak Sciences and MacroGenics.
Yes, Dermiria is publicly traded on NASDAQ under the ticker symbol DERM.
Dermiria has 10 investors. Key investors include Lilly, UCB, Canaan, Athyrium Capital Management, and Bay City Capital.
Yes. Dermiria was acquired by Lilly in January 2020.